When Bob K. was diagnosed with follicular lymphoma, he wasn’t even sure how to spell the name of the rare blood cancer. Now, as spokesperson for Epizyme’s ‘In My Blood’ digital campaign, he and other follicular lymphoma (FL) patients are talking about their experiences with the type of non-Hodgkin’s lymphoma,
Following a similar deal forged by Merck for its Covid-19 drug molnupiravir, Pfizer on Tuesday agreed to allow the UN-backed Medicines Patent Pool to license the company’s potential treatment Paxlovid…
Czech biotech Sotio will pay $29.5 million upfront with a potential $1.03 billion in downstream milestones to license five antibody-drug conjugate programs from LegoChem Biosciences, the partners…
Millions of people stuck at home during the pandemic took on do-it-yourself home projects. Now Merck wants them to turn the tables on themselves and get back to self-care. The ‘Do it For Yourself’…
When Acelyrin closed its Series A late last year, it was met with little fanfare. The biotech had only two employees, the former R&D chief and CBO of Horizon Therapeutics, and didn’t even disclose the…
UK-based AI-assisted R&D biotech Synthace just wrapped up a Series C round, bringing in $35 million. Per a company statement this morning, the investment will fuel commercial and go-to-market (GTM)…
Molecular Partners CEO Patrick Amstutz knew going into the NIH’s ACTIV-3 study that the bar for ensovibep was ‘very high.’ A slew of Covid-19 antibodies had already flunked out of the trial — and…
Viatris (formerly known as Mylan and Pfizer’s Upjohn) on Tuesday opened up on the pricing of its interchangeable biosimilar for the insulin Lantus, saying the list price would be set at about $400 for…
As Merck KGaA makes moves to treat the neglected tropical disease schistosomiasis, it has announced that its treatment arpraziquantel has yielded positive Phase III trial results in children between…
Demand for life science real estate is surging in China — and one of Asia’s largest investment groups is rising to the call. CBC Group — the startup engine that recently lured in Merck’s former R&D…
